PTCT
PTCT clinical trials: PTC THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where PTC THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 76
- Trials linked
- 65
- As lead sponsor
- 11
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PTCT on the catalyst calendar · PTCT registry changes
- Primary completion Sep 30, 2027Sponsor estimatePhase 2NCT07779616Study of PTC844 in Participants With Active Rheumatoid ArthritisPTC Therapeutics · Rheumatoid ArthritisRecruitingPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2031Sponsor estimatePhase 3NCT06302348A Study of Sepiapterin in Participants With Phenylketonuria (PKU)PTC Therapeutics · PhenylketonuriaRecruitingPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2026ActualPhase 3NCT01247207Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)PTC Therapeutics · Duchenne Muscular DystrophyTerminatedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2026ActualPhase 3NCT05166161A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPTC Therapeutics · PhenylketonuriaCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2029Sponsor estimatePhase 3NCT07681713Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)PTC Therapeutics · Friedreich's AtaxiaNot yet recruitingPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2023ActualPhase 2NCT04903288A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric...PTC Therapeutics · AADC DeficiencyActive, not recruitingPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 4, 2023ActualPhase 2/Phase 3NCT04577352A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaPTC Therapeutics · Friedreich AtaxiaCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 18, 2023ActualPhase 2/Phase 3NCT04378075A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyPTC Therapeutics · Mitochondrial DiseasesTerminatedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2025ActualNo phase registeredNCT02369731Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)PTC Therapeutics · Muscular Dystrophy, DuchenneCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 5, 2022ActualPhase 3NCT03179631Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyPTC Therapeutics · Muscular Dystrophy, DuchenneCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2025ActualPhase 3NCT05218655A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseasePTC Therapeutics · Inherited Mitochondrial DiseaseCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 3NCT05515536A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich AtaxiaPTC Therapeutics · Friedreich AtaxiaActive, not recruitingPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2024ActualPhase 2NCT05485987A Study of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaPTC Therapeutics · Friedreich AtaxiaCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2024ActualPhase 2NCT05349721Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSPTC Therapeutics · Amyotrophic Lateral SclerosisTerminatedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2024ActualPhase 2/Phase 3NCT05269355A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)PTC Therapeutics · LeiomyosarcomaTerminatedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2023ActualPhase 2NCT02352896Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromePTC Therapeutics · Leigh SyndromeCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2024ActualPhase 1NCT03761095A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)PTC Therapeutics · LeiomyosarcomaCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 7, 2023ActualPhase 2NCT04336826A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation...PTC Therapeutics · Nonsene Mutation Duchenne Muscular DystrophyCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT01370447EPI-743 for Mitochondrial Respiratory Chain DiseasesPTC Therapeutics · Mitochondrial DiseasesNo longer availablePTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 3, 2023ActualPhase 3NCT05099640A Study of PTC923 in Participants With PhenylketonuriaPTC Therapeutics · PhenylketonuriaCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2020ActualPhase 1/Phase 2NCT03519711A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With HyperphenylalaninemiaPTC Therapeutics · BH4 DeficiencyCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 20, 2022ActualPhase 2/Phase 3NCT04439071A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)PTC Therapeutics · PneumoniaTerminatedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2021ActualPhase 3NCT03783923A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)PTC Therapeutics · Limb-Girdle Muscular DystrophyTerminatedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2021ActualPhase 2NCT02647359Study of Ataluren in Participants With Nonsense Mutation AniridiaPTC Therapeutics · AniridiaCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2020ActualPhase 2NCT03648827A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)PTC Therapeutics · Duchenne Muscular DystrophyCompletedPTCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 51 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner